ATYR

aTyr Pharma, Inc.distress 1/10 · well-funded / low risk

$0.48-2%today-93% from 52w high

atyrpharma.com58 employeesFounded 2005San Diego, CABiotechnology

Lead: pulmonary sarcoidosis

Revenue

pre-revenue

Liquidity

$94M

Runway

1.6 yrs

Shares 1y

+0%

Price & events

-36.2% over 6M

CatalystRating changeDilutionFinancingdashed = today

-2.3%

-7.8%

-11.4%

-39.9%

-34.2%

-92.8%

-74.6%

-89.3%

-88.0%

All

Overview

Market Cap: $46.65M
Volume: 98.38K
52 Week Range: $0.40 – $6.61
Total Shares: 98.05M
Float Shares: 95.51M
Short %: 17.04%
% Held by Insiders: 2.45%
% Held by Institutions: 46.47%
RVOL: 0.05x
Beta: 0.52

Pipeline stages · 1 programs

efzofitimod 450 mg, efzofitimod 270 mg

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

Pipeline · 2 trials · 0 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2026-04	Phase 2	efzofitimod 450 mg, efzofitimod 270 mg	Interstitial Lung Disease	25	recruiting
2025-06-25	Phase 3	Efzofitimod 3 mg/kg, Efzofitimod 5 mg/kg	Pulmonary Sarcoidosis	268	completed

Catalyst news & presentations · 5

2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
June 2026regulatory submissionFiled (NDA/BLA)efzofitimod · Submission of IND for new Phase 3 trial in patients with restrictive lung disease.SEC 8-K
2026-05-11fda agreementefzofitimod · FDA Type C meeting feedback aligned on new Phase 3 design, endpoints, and dosing regimen.SEC 8-K
third quarter of 2025readoutPhase 3efzofitimod · Topline data expected from EFZO-FIT study.SEC 8-K
2024-07-22enrollment completesecondaryPhase 3efzofitimod · Completed enrollment in global pivotal Phase 3 EFZO-FIT trial.SEC 8-K

Approved drugs (0)

none — clinical-stage

Capital structure — dilution & financing

Shares out: 98,051,212 · 0 offerings/1y · 0 PIPEs

2025-08-18EFFECTshelf_effective
2025-08-07S-3shelf_registration
2024-12-238-Kmaterial_agreement
2024-12-23424B5offering
2024-11-14SC 13G/Astrategic_stake
2024-10-15SC 13Gstrategic_stake
2024-10-07SC 13G/Astrategic_stake

🔒 Positioning — Pro

Short interest / days-to-cover, insider buys & sells.

Upgrade to Pro

🔒 Top holders — Pro

Institutional ownership + quarter-over-quarter accumulation/trimming.

Upgrade to Pro

Wall St ratings

buy · target $3 (+500% upside) · 7 analysts

2026-05-20Freedom BrokerHold → Buy
2025-11-07RBC CapitalSector Perform
2025-09-16Wells FargoOverweight → Equal-Weight
2025-09-16RBC CapitalOutperform → Sector Perform
2025-09-15Leerink PartnersOutperform → Market Perform
2025-09-15Jones TradingBuy → Hold

Competitors — pulmonary sarcoidosis

none identified

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.